Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Puretech Health PLC    PRTC   GB00BY2Z0H74

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Puretech Health : Results of Annual General Meeting

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/09/2017 | 07:25pm CEST

9 May 2017

PureTech Health plc Results of Annual General Meeting

The Annual General Meeting of PureTech Health plc ("PureTech", LSE: PRTC) plc was held at 17.00 BST on Monday 8 May 2017. All of the resolutions proposed at the Annual General Meeting were duly passed by the shareholders on a poll.

The results of the poll, incorporating the proxy votes lodged in advance of the meeting, are set out below.

Resolutions

For

%

Against

%

Withheld

Total votes cast

001. To approve the Company's Annual Report and Accounts for year end 31 December 2016

179,399,131

100.00

0

0.00

0

179,399,131

002. To approve the Directors' Remuneration Report

174,260,790

97.14

5,138,341

2.86

0

179,399,131

003. To elect Mr. Joichi Ito as a Director

179,399,131

100.00

0

0.00

0

179,399,131

004. To elect Dr. Raju Kucherlapati as a Director

179,399,131

100.00

0

0.00

0

179,399,131

005. To elect Dr. John LaMattina as a director

179,399,131

100.00

0

0.00

0

179,399,131

006. To elect Dame Marjorie Scardino as a director

179,399,131

100.00

0

0.00

0

179,399,131

007. To elect Mr. Christopher Viehbacher as a director

179,399,131

100.00

0

0.00

0

179,399,131

008. To elect Dr. Robert Langer as a director

175,561,073

97.95

3,665,851

2.05

172,207

179,226,924

009. To elect Dr. Bennett Shapiro as a director

173,797,010

96.97

5,429,914

3.03

172,207

179,226,924

010. To elect Ms. Daphne Zohar as a director

179,399,131

100.00

0

0.00

0

179,399,131

011. To elect Mr. Stephen Muniz as a director

179,399,131

100.00

0

0.00

0

179,399,131

012. To reappoint KPMG LLP as Auditors of the Company

179,399,131

100.00

0

0.00

0

179,399,131

013. To authorise the Board of Directors to determine the Auditors' remuneration

179,399,131

100.00

0

0.00

0

179,399,131

014. To authorise the allotment of shares

173,622,534

96.78

5,776,597

3.22

0

179,399,131

015. To dis-apply pre-emption rights

179,109,365

99.84

289,766

0.16

0

179,399,131

016. To dis-apply pre-emption rights in limited circumstances

173,622,534

96.78

5,776,597

3.22

0

179,399,131

017. To authorise market purchase of own shares

179,109,365

99.84

289,766

0.16

0

179,399,131

018. To authorise general meetings to be called on not less than 14 clear days' notice

178,716,991

99.62

682,140

0.38

0

179,399,131

Due to its shareholding in the Company, Invesco Asset Management Limited is deemed to be a controlling shareholder as defined in the Financial Conduct Authority's Listing Rules. Accordingly, each resolution to elect an independent director (resolutions 4, 5, 6 and 7) has under Listing Rule 9.2.2E been approved by a majority of the votes cast by:

  • the shareholders of the Company as a whole; and

  • the independent shareholders of the Company, that is, all the shareholders entitled to vote on each resolution excluding the controlling shareholder as shown below.

Resolutions

For

%

Against

%

Withheld

Total votes cast

004. To elect Dr. Raju Kucherlapati as a Director

103,602,134

100

0

0

0

103,602,134

005. To elect Dr. John LaMattina as a director

103,602,134

100

0

0

0

103,602,134

006. To elect Dame Marjorie Scardino as a director

103,602,134

100

0

0

0

103,602,134

007. To elect Mr. Christopher Viehbacher as a director

103,602,134

100

0

0

0

103,602,134

Notes:

A vote "Withheld" is not a vote in law and is not counted in the calculation of the votes "For" or "Against" a resolution.

As at 8 May 2017, the number of issued shares in the Company was 237,387,951 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.

The full text of the resolutions may be found in the Notice of the Annual General Meeting, copies of which are available on both the Company's website www.puretechhealth.com and on the National Storage Mechanism.

In accordance with Listing Rule 9.6.2, a copy of the resolutions, other than those concerning ordinary business has been submitted to the National Storage Mechanism and will shortly be available for inspection at: www.morningstar.co.uk/uk/NSM.

About PureTech Health

PureTech Health (PureTech Health plc, PRTC.L) is an advanced, clinical-stage biopharmaceutical company developing novel medicines that modulate the adaptive human systems. PureTech's therapies target the dysfunctions in the immune, nervous, and gastro-intestinal systems by addressing the underlying pathophysiology of disease from a systems perspective rather than through a single receptor or pathway. The Company is advancing a rich pipeline that includes multiple human proof- of-concept studies and pivotal or registration studies expected to read out over the next 12-18 months. PureTech Health's growing research and development pipeline has been developed in collaboration with some of the world's leading scientific experts, who along with PureTech's experienced team and a stellar Board identify, analyse and advance very selectively the opportunities the Company believes hold the most promise for patients. This experienced and engaged team places PureTech Health at the forefront of ground-breaking science and technological innovation and leads the Company between and beyond existing disciplines. For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.

Forward Looking Statement

This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments and strategies. The forward- looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

For further information: PureTech Health FTI Consulting

Allison Mead

+1 617 651 3156

amead@puretechhealth.com

Ben Atwell, Matthew Cole, Rob Winder

+44 (0) 20 3727 1000

PureTech Health plc published this content on 09 May 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 09 May 2017 17:25:23 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PURETECH HEALTH PLC
08/15 PURETECH HEALTH : Notice of Half-Yearly Results
07/13 PURETECH HEALTH : Presents Data Supporting Treatment Approach for Interstitial C..
07/12 PURETECH HEALTH : Gelesis Announces Last Patient Visit in the Pivotal Gelesis100..
07/12 PURETECH HEALTH : Gelesis Announces Last Patient Out in the Pivotal Gelesis100 W..
06/28 PURETECH HEALTH : Akili Appoints Former Cubist CEO, Rob Perez, as Executive Chai..
06/28 PURETECH HEALTH : Former Cubist CEO, DreamWorks Interactive CEO, and Google Chie..
06/01 PURETECH HEALTH : to Present at Jefferies 2017 Global Healthcare Conference
05/30 PURETECH HEALTH : Vedanta Biosciences Granted U.S. Patent Broadly Covering Metho..
05/30 VEDANTA BIOSCIENCES : Granted U.S. Patent Broadly Covering Methods of Treatment ..
05/25 PURETECH HEALTH : Vedanta Biosciences Granted Three U.S. Patents Broadly Coverin..
More news
Financials ($)
Sales 2017 1,85 M
EBIT 2017 -100 M
Net income 2017 -66,8 M
Finance 2017 41,1 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 199x
EV / Sales 2018 208x
Capitalization 410 M
Chart PURETECH HEALTH PLC
Duration : Period :
Puretech Health PLC Technical Analysis Chart | PRTC | GB00BY2Z0H74 | 4-Traders
Technical analysis trends PURETECH HEALTH PLC
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 3,13 $
Spread / Average Target 81%
Managers
NameTitle
Daphne Zohar Chief Executive Officer & Executive Director
Bharatt M. Chowrira President, Chief Business & Strategy Officer
Joichi Ito Non-Executive Chairman
Stephen Muniz Chief Operations Officer, Secretary & Director
Michael F. MacLean Chief Financial Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
PURETECH HEALTH PLC13.89%418
INCYTE CORPORATION26.03%25 995
QUINTILES IMS HOLDINGS INC18.33%19 819
LONZA GROUP37.66%17 539
CELLTRION, INC.--.--%11 245
ALKERMES PLC-7.12%7 929